drugset / Trial / NCT03421379

A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

NCT03421379

Phase 3 Completed 75 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus.

Timeline

Start
2018-02-21
Primary completion
2018-08-20
Completion
2018-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon Peptide 1 mg Intranasal
Subject Glucagon Peptide 3 mg Intranasal

Indications